Nodal Marginal Zone Lymphoma Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Nodal Marginal Zone Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more
UNC Lineberger Comprehensive Cancer Center20 enrolled1 locationNCT04223765
Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)300 enrolled36 locationsNCT05700149
Recruiting
Phase 2

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

Extranodal Marginal Zone Lymphoma
Izidore Lossos, MD35 enrolled1 locationNCT06569680
Recruiting
Phase 2

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Marginal Zone LymphomaSplenic Marginal Zone LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+1 more
Izidore Lossos, MD25 enrolled1 locationNCT06796998
Recruiting
Phase 2

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRecurrent Nodal Marginal Zone LymphomaRefractory Diffuse Large B-Cell Lymphoma+11 more
Joseph Tuscano25 enrolled1 locationNCT06905509
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008